Report

Global Ankylosing Spondylitis Market Size study & Forecast, by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Analysis, 2022-2029

  • Publish Date: Jan,2023
  • Report ID: 3-2-1370
  • Page : 200
  • Report Type : PDF (Email)
Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Ankylosing Spondylitis Market, by Region, 2019-2029 (USD Billion)
1.2.2. Ankylosing Spondylitis Market, by Drug Class, 2019-2029 (USD Billion)
1.2.3. Ankylosing Spondylitis Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Ankylosing Spondylitis Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Ankylosing Spondylitis Market Dynamics
3.1. Ankylosing Spondylitis Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Growing prevalence of Arthritis.
3.1.1.2. Growing incidences of Ankylosing Spondylitis
3.1.1.3. Strategic initiatives from leading market players
3.1.2. Market Challenges
3.1.2.1. High treatment cost of Ankylosing Spondylitis
3.1.3. Market Opportunities
3.1.3.1. Growing number of orthopedic hospitals and diagnostic centers
3.1.3.2. Rising healthcare infrastructure in developing regions.
Chapter 4. Global Ankylosing Spondylitis Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Ankylosing Spondylitis Market, by Drug Class
6.1. Market Snapshot
6.2. Global Ankylosing Spondylitis Market by Drug Class, Performance - Potential Analysis
6.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
6.4. Ankylosing Spondylitis Market, Sub Segment Analysis
6.4.1. NSAIDs
6.4.2. TNF inhibitors
6.4.3. Others
Chapter 7. Global Ankylosing Spondylitis Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Ankylosing Spondylitis Market by Distribution Channel, Performance - Potential Analysis
7.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
7.4. Ankylosing Spondylitis Market, Sub Segment Analysis
7.4.1. Hospital pharmacy
7.4.2. Retail pharmacy
7.4.3. Online pharmacy
Chapter 8. Global Ankylosing Spondylitis Market, Regional Analysis
8.1. Ankylosing Spondylitis Market, Regional Market Snapshot
8.2. North America Ankylosing Spondylitis Market
8.2.1. U.S. Ankylosing Spondylitis Market
8.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Ankylosing Spondylitis Market
8.3. Europe Ankylosing Spondylitis Market Snapshot
8.3.1. U.K. Ankylosing Spondylitis Market
8.3.2. Germany Ankylosing Spondylitis Market
8.3.3. France Ankylosing Spondylitis Market
8.3.4. Spain Ankylosing Spondylitis Market
8.3.5. Italy Ankylosing Spondylitis Market
8.3.6. Rest of Europe Ankylosing Spondylitis Market
8.4. Asia-Pacific Ankylosing Spondylitis Market Snapshot
8.4.1. China Ankylosing Spondylitis Market
8.4.2. India Ankylosing Spondylitis Market
8.4.3. Japan Ankylosing Spondylitis Market
8.4.4. Australia Ankylosing Spondylitis Market
8.4.5. South Korea Ankylosing Spondylitis Market
8.4.6. Rest of Asia Pacific Ankylosing Spondylitis Market
8.5. Latin America Ankylosing Spondylitis Market Snapshot
8.5.1. Brazil Ankylosing Spondylitis Market
8.5.2. Mexico Ankylosing Spondylitis Market
8.6. Rest of The World Ankylosing Spondylitis Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. AbbVie Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Amgen, Inc,
9.2.3. Eli Lilly and Company
9.2.4. Gilead Sciences Inc
9.2.5. Janssen Pharmaceuticals
9.2.6. Merck & Co. Inc
9.2.7. Novartis AG,
9.2.8. Pfizer, Inc
9.2.9. Reliance Life Sciences Pvt. Ltd
9.2.10. UCB, Inc.,
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption